Comparative study to evaluate efficacy & cost effectiveness of Olmesartan versus Telmisartan, in patients of stage I hypertension.
Loading...
Date
2015-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: Hypertension is one of the most common diseases
in the world. It is an important and independent risk factor for
atherosclerosis, heart failure, renal disease, and peripheral
arterial disease. It is directly responsible for 57% of all stroke
deaths and 42% of coronary heart disease deaths in India
Objectives: To evaluate and compare efficacy and cost
effectiveness in hypertensive patients receiving Olmesartan and
Telmisartan in Stage I hypertension
Material and methods: The present study was an open,
prospective, randomized, parallel group comparative study
conducted in 60 patients of stage I hypertension over a period of
16 weeks. Patients were randomly allocated to two, age and sex,
matched groups of 30 patients each. Group I patients were
started on Olmesartan at a dose of 20 mg & Group II patients
were put on Telmisartan at a dose of 40 mg. The BP lowering
efficacy and cost effective analysis of Olmesartan versus
Telmisartan was calculated & compared. The data was entered in
Microsoft excel and compiled. Statistical analysis was done using
various tests.
Results: Maximum patients in both the groups were in age group
of 51-60 years. In group I there were 13 males and 17 females. In
group II there were 14 males and 16 females. Both Olmesartan
and Telmisartan are effective in lowering systolic & diastolic BP in
supine & sitting positions & mean BP is also lowerer, more in Olmesartan group. By cost effective analysis
Telmisartan was found more cost effective. Incremental cost effective ratio was found to be 218.35.
Conclusion: Both Olmesartan and Telmisartan belong to the same antihypertensive drug class, effectively
reduce systolic and diastolic blood pressure at various visits. Taking into account Total cost Telmisartan was
more cost effective than Olmesartan. ICER was found to be 218.35.
Description
Keywords
Olmesartan, telmisartan, cost effectiveness, hypertension, angiotensin receptor blockers
Citation
Palta S, Sehgal VK, Gupta AK, Singh H. Comparative study to evaluate efficacy & cost effectiveness of Olmesartan versus Telmisartan, in patients of stage I hypertension. International Journal of Medical and Dental Sciences. 2015 Jan; 4(1): 568-576.